中国肺癌杂志2024，Vol.27Issue(11)：873-877,5.DOI:10.3779/j.issn.1009-3419.2024.102.36
赛沃替尼诱导MET扩增非小细胞肺癌病理学完全缓解1例
Savolitinib Induced Pathological Complete Response in Non-small Cell Lung Cancer with MET Amplification:A Case Report
摘要
Abstract
Mesenchymal-epithelial transition factor(MET)gene mutation is a large class of mutations commonly seen in non-small cell lung cancer(NSCLC).MET mutation includes subtypes such as MET exon 14 skipping mutation(ME-Tex14m)and MET amplification(METamp).For advanced NSCLC with METex14m,Savolitinib has a high sensitivity as a member of tyrosine kinase inhibitors(TKIs).METamp is a relatively rare genetic mutation type which can serve as a driver gene to mediate primary and later acquired drug resistance of epidermal growth factor receptor(EGFR)-TKIs.For advanced NSCLC with secondary METamp,EGFR-TKIs combined with MET-TKIs are usually used in clinical treatment,while the optimal treatment strategy for advanced NSCLC with primary METamp has not yet been determined.For locally advanced NSCLC patients with positive driver gene mutations such as EGFR,anaplastic lymphoma kinase(ALK)fusion and ME-Tex14m,there have been relevant cases reported that neoadjuvant targeted therapy could achieve a good prognosis,but there have been no cases of neoadjuvant targeted therapy for locally advanced NSCLC patients with METamp.This report describes a case of a locally advanced NSCLC patient with dual driver gene mutations(EGFR L858R combined with primary METamp),the tumor did not shrink after 1 month of Gefitinib monotherapy,but significantly subsided after 4 months of Savolitinib monotherapy.After radical surgery,the pathological results proved pathological complete response(pCR)of the tumor,and the patient had a good response to postoperative continual Savolitinib treatment,with no recurrence nor metastasis observed to date.This case reports the feasibility and effectiveness of neoadjuvant targeted therapy for locally advanced NSCLC with primary METamp,aiming to provide effective reference for perioperative treatment of locally advanced NSCLC with primary METamp.关键词
肺肿瘤/新辅助靶向治疗/MET扩增/赛沃替尼/病理学完全缓解Key words
Lung neoplasms/Neoadjuvant targeted therapy/MET amplification/Savolitinib/Pathological com-plete response引用本文复制引用
鲁蒙,张然,李百玮,徐海迪,郭永宽,尤健,孙冰生..赛沃替尼诱导MET扩增非小细胞肺癌病理学完全缓解1例[J].中国肺癌杂志,2024,27(11):873-877,5.基金项目
本文受天津市医学重点学科(专科)建设项目(No.TJYXZDXK-010A)资助 This paper was supported by the grant from Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-010A)(to Tianjin Medical University Cancer Institute & Hospital). （专科）
